| MeSH term | MeSH ID | Detail |
|---|---|---|
| Asthenia | D001247 | 5 associated lipids |
| Body Weight | D001835 | 333 associated lipids |
| Brain Diseases | D001927 | 27 associated lipids |
| Breast Neoplasms | D001943 | 24 associated lipids |
| Bronchial Spasm | D001986 | 18 associated lipids |
| Colonic Neoplasms | D003110 | 161 associated lipids |
| Hyperplasia | D006965 | 34 associated lipids |
| Hypopharyngeal Neoplasms | D007012 | 1 associated lipids |
| Leukemia | D007938 | 74 associated lipids |
| Leukemia P388 | D007941 | 43 associated lipids |
MAYTANSINE
MAYTANSINE is a lipid of Polyketides (PK) class. Maytansine is associated with abnormalities such as Myelosuppression and BOSLEY-SALIH-ALORAINY SYNDROME. The involved functions are known as Mutation, Agent, Polymerization, Cell Cycle Arrest and Drug Kinetics. Maytansine often locates in Cytoplasm, Hepatic, Lysosomes, Cell surface and Microtubules. The associated genes with MAYTANSINE are ABCB1 gene, HM13 gene, CNN1 gene, CYP2C8 gene and CYP2D6 gene. The related lipids are Valerates. The related experimental models are Xenograft Model.
Cross Reference
Introduction
To understand associated biological information of MAYTANSINE, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with MAYTANSINE?
MAYTANSINE is suspected in Myelosuppression, BOSLEY-SALIH-ALORAINY SYNDROME and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with MAYTANSINE
PubChem Associated disorders and diseases
What pathways are associated with MAYTANSINE
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with MAYTANSINE?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with MAYTANSINE?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with MAYTANSINE?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with MAYTANSINE?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with MAYTANSINE?
Xenograft Model
Xenograft Model are used in the study 'IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.' (Ab O et al., 2015).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with MAYTANSINE
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Krop IE et al. | Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. | 2014 | Lancet Oncol. | pmid:24793816 |
| Gnant M et al. | HER2-positive breast cancer: a new piece of the puzzle. | 2014 | Lancet Oncol. | pmid:24793817 |
| Yaqub F | T-DM1 for HER2-positive metastatic breast cancer. | 2013 | Lancet Oncol. | pmid:23580966 |
| Hurvitz SA et al. | Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. | 2018 | Lancet Oncol. | pmid:29175149 |
| Thuss-Patience PC et al. | Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. | 2017 | Lancet Oncol. | pmid:28343975 |
| Venkatesan P | Trastuzumab emtansine for HER2-positive breast cancer. | 2016 | Lancet Oncol. | pmid:27866859 |
| Loibl S and Gianni L | HER2-positive breast cancer. | 2017 | Lancet | pmid:27939064 |
| Dholaria B and Srinivasan S | T-DM1-related carotenoderma and hand-foot syndrome. | 2015 | Lancet | pmid:25933279 |
| Kashiwaba M et al. | A multicenter Phase II study evaluating the efficacy, safety and pharmacokinetics of trastuzumab emtansine in Japanese patients with heavily pretreated HER2-positive locally recurrent or metastatic breast cancer. | 2016 | Jpn. J. Clin. Oncol. | pmid:26917603 |
| Yamamoto H et al. | Phase I and pharmacokinetic study of trastuzumab emtansine in Japanese patients with HER2-positive metastatic breast cancer. | 2015 | Jpn. J. Clin. Oncol. | pmid:25332421 |
| Okamoto K et al. | Therapeutic effect of ansamitocin targeted to tumor by a bispecific monoclonal antibody. | 1992 | Jpn. J. Cancer Res. | pmid:1517150 |
| Hayashi T et al. | Targeting HER2 with T-DM1, an Antibody Cytotoxic Drug Conjugate, is Effective in HER2 Over Expressing Bladder Cancer. | 2015 | J. Urol. | pmid:26047983 |
| Fellous A et al. | Removal of the projection domain of microtubule-associated protein 2 alters its interaction with tubulin. | 1994 | J. Protein Chem. | pmid:7986343 |
| Xie H et al. | Pharmacokinetics and biodistribution of the antitumor immunoconjugate, cantuzumab mertansine (huC242-DM1), and its two components in mice. | 2004 | J. Pharmacol. Exp. Ther. | pmid:14634038 |
| Kupchan SM et al. | The maytansinoids. Isolation, structural elucidation, and chemical interrelation of novel ansa macrolides. | 1977 | J. Org. Chem. | pmid:874612 |
| Bartsch R et al. | Breast cancer brain metastases responding to primary systemic therapy with T-DM1. | 2014 | J. Neurooncol. | pmid:24065570 |
| Geraud A et al. | Preliminary experience of the concurrent use of radiosurgery and T-DM1 for brain metastases in HER2-positive metastatic breast cancer. | 2017 | J. Neurooncol. | pmid:27995546 |
| de Vries CL et al. | Response of symptomatic brain metastases from HER-2 overexpressing breast cancer with T-DM1. | 2016 | J. Neurooncol. | pmid:26732082 |
| Altundag K | Radio-sensitising effect of T-DM1 should not be discarded for the efficacy of radiosurgery in the management of brain metastases in patients with HER2-positive metastatic breast cancer. | 2017 | J. Neurooncol. | pmid:28337582 |
| Sato Y et al. | Induction of neurofibrillary tangles in cultured mouse neurons by maytanprine. | 1985 | J. Neurol. Sci. | pmid:4040155 |